Further providing for definitions; and providing for medical marijuana exemption.
Summary
SB1274 amends Pennsylvania’s Controlled Substance, Drug, Device and Cosmetic Act to revise and expand definitions related to hemp and hemp-derived cannabinoid products. It defines terms such as “container,” “final hemp-derived cannabinoid product,” “hemp,” “hemp-derived cannabinoid product,” “industrial hemp,” and “intermediate hemp-derived cannabinoid product,” and it narrows what hemp-derived products may qualify as hemp under state law. The bill excludes certain synthesized or manufactured cannabinoids, intermediate products marketed as final consumer goods, and products exceeding specified THC or THC-like cannabinoid thresholds.
The bill also revises the definition of “marihuana” to expressly include hemp-derived cannabinoid products, while carving out a medical marijuana exemption. Under the new section, marijuana derived from a medical marijuana organization or handled under the Medical Marijuana Act would not be considered a violation of the Controlled Substance Act. The measure is set to take effect on November 12, 2026, or immediately if later.
Impact
SB1274 would change how Pennsylvania law classifies hemp, hemp-derived cannabinoid products, and marijuana by adding detailed statutory definitions and limits on cannabinoid content. It would likely affect hemp processors, retailers, manufacturers, consumers, and regulators by drawing a clearer line between lawful hemp products and controlled substances, especially for intoxicating or chemically altered cannabinoid products. It also creates an explicit statutory exemption for medical marijuana activity under the Medical Marijuana Act, reducing the risk that medical marijuana operations or patients are treated as violating the Controlled Substance Act.
Sentiment
No committee transcript or vote record is provided, so there is no documented floor or committee sentiment to assess. Based on the bill text, the measure appears aimed at clarifying and tightening regulation of hemp-derived cannabinoid products while preserving the existing medical marijuana program, suggesting a regulatory rather than punitive approach. The absence of recorded debate or votes means support or opposition cannot be measured from the available materials.
Contention
The main likely point of contention is the treatment of hemp-derived cannabinoid products, especially products containing cannabinoids that are synthesized, manufactured outside the plant, or marketed in ways that resemble intoxicating cannabis products. Stakeholders in the hemp industry may object to the bill’s narrow thresholds and broad inclusion of hemp-derived cannabinoid products within the marihuana definition, while regulators and public health advocates may support the tighter controls. The medical marijuana exemption appears designed to avoid conflict with the Medical Marijuana Act, but the boundary between hemp products, intoxicating cannabinoids, and medical cannabis could still be disputed.
In preliminary provisions, further providing for definitions; in practitioners, further providing for pr actitioner registration; in medical marijuana controls, further providing for electronic tracking and for laboratory; and, in Medical Marijuana Advisory Board, further providing for advisory board.
AN ACT to create and enact section 19-24.1-24.1 and a new subsection to section 19-24.1-36 of the North Dakota Century Code, relating to regulating edible medical marijuana products; and to amend and reenact section 19-24.1-01 of the North Dakota Century Code, relating to definitions of medical marijuana products.
AN ACT to amend Tennessee Code Annotated, Title 39; Title 40; Title 43, Chapter 27; Title 53, Chapter 11; Title 57 and Title 67, relative to the regulation of hemp-derived cannabinoid products.